A Study of Empirical Antifungal Therapy With Itraconazole
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01706562|
Recruitment Status : Completed
First Posted : October 15, 2012
Last Update Posted : February 20, 2013
|Condition or disease||Intervention/treatment|
|Study Type :||Observational|
|Actual Enrollment :||138 participants|
|Official Title:||Retrospective Observation of Empirical Antifungal Therapy With Itraconazole|
|Study Start Date :||May 2011|
|Actual Primary Completion Date :||September 2011|
|Actual Study Completion Date :||September 2011|
Itraconazole intravenous (IV) 200 mg twice daily for 2 days, a total of 4 doses and then 200 mg once daily until clinically significant resolution of neutropenia.
- Success rate of itraconazole treatment when used for more than 7 days [ Time Frame: From 7 days to approximately 2 weeks ]Treatment success is achieved when neutropenia is resolved, ie, when the blood cells count is within the normal reference range.
- Success rate of itraconazole treatment until neutropenia is resolved [ Time Frame: Approximately 2 weeks ]Treatment success is achieved when neutropenia is resolved, ie, when the blood cells count is within the normal reference range.
- Drop out rate due to the lack of efficacy of itraconazole treatment [ Time Frame: Approximately 2 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01706562
|Study Director:||Janssen Korea, Ltd., Korea Clinical Trial||Janssen Korea, Ltd., Korea|